Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bakris

Showing results (691-700 of 738) with videos related to

Pageof 74
Sort By:
Diabetes Care|September 25, 2014
Diabetic kidney disease: a report from an ADA Consensus ConferenceKatherine R Tuttle, George L Bakris, Rudolf W Bilous, et al.
JACC. Heart Failure|June 30, 2022
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart FailureJ David Smeijer, Jeroen Koomen, Donald E Kohan, et al.
Clinical Pharmacology and Therapeutics|July 27, 2022
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney DiseaseJ David Smeijer, Jeroen V Koomen, Donald E Kohan, et al.
American Heart Journal|July 29, 2008
Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortalityPeter A McCullough, Suying Li, Claudine T Jurkovitz, et al.
Diabetes|December 17, 2016
Differentiation of Diabetes by Pathophysiology, Natural History, and PrognosisJay S Skyler, George L Bakris, Ezio Bonifacio, et al.
American Heart Journal|December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trialAshish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International|December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practiceMegumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Journal of Hypertension|August 19, 2022
Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of HypertensionGeorge Stergiou, Mattias Brunström, Thomas MacDonald, et al.
Lancet (London, England)|April 19, 2019
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 31, 2013
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trialHiddo J Lambers Heerspink, Glenn M Chertow, Tadao Akizawa, et al.
Pageof 74

Showing results (691-700 of 738) with videos related to

Sort By:
Pageof 74
Diabetes Care|September 25, 2014
Diabetic kidney disease: a report from an ADA Consensus ConferenceKatherine R Tuttle, George L Bakris, Rudolf W Bilous, et al.
JACC. Heart Failure|June 30, 2022
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart FailureJ David Smeijer, Jeroen Koomen, Donald E Kohan, et al.
Clinical Pharmacology and Therapeutics|July 27, 2022
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney DiseaseJ David Smeijer, Jeroen V Koomen, Donald E Kohan, et al.
American Heart Journal|July 29, 2008
Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortalityPeter A McCullough, Suying Li, Claudine T Jurkovitz, et al.
Diabetes|December 17, 2016
Differentiation of Diabetes by Pathophysiology, Natural History, and PrognosisJay S Skyler, George L Bakris, Ezio Bonifacio, et al.
American Heart Journal|December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trialAshish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International|December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practiceMegumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Journal of Hypertension|August 19, 2022
Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of HypertensionGeorge Stergiou, Mattias Brunström, Thomas MacDonald, et al.
Lancet (London, England)|April 19, 2019
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 31, 2013
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trialHiddo J Lambers Heerspink, Glenn M Chertow, Tadao Akizawa, et al.
Pageof 74